miR-486 is involved in the pathogenesis of acute myeloid leukemia by regulating JAK-STAT signaling
Authors:
- 29 May 2020
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 394 (1) , 177-187
Abstract
Acute myeloid leukemia (AML) is a widely prevalent disease worldwide and poses a large threat to public health. Previous studies have shown that AML is associated with cytogenetic heterogeneity, complex subtypes, and different therapeutic approaches. In this study, we found that miR-486 was upregulated in AML using both The Cancer Genome Atlas (TCGA) database and patient tissues. After knockdown of miR-486 by short hairpin RNA (shRNA), we discovered that miR-486 was required for cell proliferation. Through miRNA profile analysis and a dual-luciferase reporter assay, suppressor of cytokine signaling 2 (SOCS2) was identified as a direct target of miR-486. Therefore, by silencing SOCS2, a negative regulator of the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway, miR-486 enhanced JAK-STAT3 activity and promoted cell proliferation. The miR-486-SOCS2-STAT3 proliferation axis is therefore involved in the pathogenesis of AML, providing a novel molecular mechanism and diagnostic and therapeutic clues for AML.Keywords
This publication has 37 references indexed in Scilit:
- Regulation of type I interferon responsesNature Reviews Immunology, 2013
- miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia –rearranged leukemiaProceedings of the National Academy of Sciences, 2013
- Targeting the tumor microenvironmentJAK-STAT, 2013
- Silencing SOCS3 could inhibit TNF-α induced apoptosis in 3T3-L1 and mouse preadipocytesMolecular Biology Reports, 2012
- The microcosmos of cancerNature, 2012
- Microribonucleic acids and gastric cancerCancer Science, 2012
- The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signalingOncogene, 2009
- Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activityProceedings of the National Academy of Sciences, 2007
- Stattic: A Small-Molecule Inhibitor of STAT3 Activation and DimerizationChemistry & Biology, 2006
- IRF-7 is the master regulator of type-I interferon-dependent immune responsesNature, 2005